Consortium for the study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Consortium – Pittsburgh Clinical Center

点击翻译按钮获取中文摘要

Abstract. Consortium for the Study of Pancreatitis: Pittsburgh Clinical Center. The Consortium for the Study of Pancreatitis: Pittsburgh Clinical Center (PCC) is a multidisciplinary clinical- translational program at the University of Pittsburgh and UPMC. The PCC is one of the 10 founding members of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). The organizational structure of PCC allows comprehensive epidemiological, clinical and biological characterization of patients with pancreatic disorders in order to conduct clinical, translational and mechanistic studies of recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) and their sequelae such as Type 3c diabetes and pancreatic cancer. The PCC is highly integrated at all levels of the CPDPC, including leadership, participation in Committees and Working Groups, contribution to primary cohorts, several ancillary studies and publications. PCC has been effective in utilizing the CPDPC infrastructure and resources for high-quality scientific projects. In the next five years of funding, the PCC is committed to completing ascertainment of the primary CPDPC cohorts, execution of the currently approved ancillary studies, and participating in new projects. We will also propose concepts for three new ancillary studies that will utilize the infrastructure and resources of the CPDPC. Our specific aims are: Aim 1. Contribute to completing the acquisition of CPDPC’s primary cohorts and ongoing ancillary studies. Aim 2. We will propose and support new ancillary projects to use the infrastructure created with the primary cohorts and ongoing ancillary studies. As part of Aim 2, we propose concepts for three ancillary projects, to – i) Develop a Chronic Pancreatitis Risk Score (CPRS) for use in randomized clinical trials of CP, ii) Identify Urine Biomarkers of Pain (UBP) for mechanism-based phenotyping of CP pain, and iii) Use a genotying approach to enrich the New Onset Diabetes (NOD) cohort. Our existing and well-established, efficient and effective clinical and research infrastructure for patient accrual, sample processing, data management and transfer, and analysis will support the program. The rich clinical volume, diverse investigator expertise in all critical areas such as pancreatology, epidemiology, early detection of cancer, genetics, physiology, imaging, endocrinology, biostatistics and bioinformatics, and all relevant disease subtypes, administrative authority in clinical and research areas ensure continued success. Our track record of leadership, strong collaborations and working relationships within the CPDPC and other collaborative networks will also ensure continued success and effectiveness of the CPDPC.